Unveiling next-generation tools
for inhalation risk assessment

This introductory webinar will provide valuable insights into the evolving landscape of safety assessments.

Wednesday, November 8th

2:00 pm - 2:50 pm

What you'll learn:

  • Explore ImmuONE's innovative solutions and how they can be customised to meet your unique needs
  • Hear case-study examples of how ImmuONE services have addressed safety assessments

This is your opportunity to stay at the forefront of safety assessment innovation

Prof. Victoria Hunter

Chief Scientific Officer

Victoria spent 8 years at the University of Hertfordshire from lecturer to associate professor and established her own independent research team; securing over £6M funding in topical drug delivery and toxicology. This supported the development of new innovations and IP in novel human cell culture models and techniques as alternatives to animal testing.

Dr Victoria Hunter co-founded ImmuONE in 2019 with Abigail after a successful Innovation to Commercialisation of University Research (ICURe) programme which allowed us to accelerate our human in vitro immunocompetent lung models to market. Her role as Chief Scientific Officer spans the scientific and commercial aspects of the company.

Dr Louis Scott
Client Relations Manager

Louis is a true believer in the need for robust, animal-free, and human-relevant models in toxicity testing and is an immunologist by trade.

“Exploring the modulation of macrophage biology in commercial testing is pivotal for understanding important aspects of how lungs and bodies are affected by inhaled compounds.

Immune cells are our knights in shining armour when it comes to protecting our body, and by that logic, ensuring their health is incredibly important.”